1. Home
  2. GSIT vs SABS Comparison

GSIT vs SABS Comparison

Compare GSIT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GSI Technology

GSIT

GSI Technology

HOLD

Current Price

$7.32

Market Cap

213.6M

Sector

Technology

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$4.40

Market Cap

187.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIT
SABS
Founded
1995
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.6M
187.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GSIT
SABS
Price
$7.32
$4.40
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
1.8M
444.5K
Earning Date
01-29-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,024,000.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.00
N/A
52 Week Low
$1.62
$1.00
52 Week High
$18.15
$6.60

Technical Indicators

Market Signals
Indicator
GSIT
SABS
Relative Strength Index (RSI) 48.83 71.33
Support Level $7.10 $3.93
Resistance Level $8.05 $4.65
Average True Range (ATR) 0.91 0.27
MACD -0.07 0.05
Stochastic Oscillator 18.26 79.84

Price Performance

Historical Comparison
GSIT
SABS

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: